CervoMed to Participate in September Investor Conferences

CervoMed to Present at Key September Investor Conferences to Discuss Neurodegenerative Drug Development Progress

CervoMed Inc., a clinical-stage biotech developing treatments for age-related brain disorders, announced management's participation in major September investor conferences. The company highlighted its lead drug candidate neflamapimod's progress, including a completed Phase 2b trial in dementia with Lewy bodies (DLB), discussions with the FDA on registration path, ongoing Phase 2a trials in frontotemporal disorders, and upcoming ALS trial dosing. Advancement to Phase 3 depends on partnerships or financing.

CervoMed to Participate in September Investor Conferences

CRVO

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

CervoMed to present at Cantor Global Healthcare and H.C. Wainwright Global Investment Conferences in September 2026.
Lead drug, neflamapimod, targets neuroinflammation and neurodegeneration and recently completed Phase 2b RewinD-LB trial for DLB.
Phase 3 trial initiation contingent on partnerships or additional financing; interim Phase 2a biomarker data expected early Q4 2026.
Sectors impacted include biotechnology, pharmaceuticals with a focus on neurology and neurodegenerative diseases.

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:

Cantor Global Healthcare Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Friday, September 11, 2026
Time: 10:55 – 11:25 AM ET

Webcast Link:
https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1

H.C. Wainwright Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 – 4:30 PM ET

Webcast Link:
https://journey.ct.events/view/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts:

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902

Risks

Advancement to Phase 3 clinical trials is subject to securing a partnership or additional financing, which introduces funding risk.
Clinical trial outcomes, particularly from ongoing Phase 2a studies, remain uncertain and could delay development timelines.
Regulatory approval depends on FDA alignment and future trial results; failure to meet endpoints could impact market prospects.

Menu

CervoMed to Participate in September Investor Conferences

Key Points

Risks

More from Press Releases